Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission

Tetsuya Eto, Ken Takase, Toshihiro Miyamoto, Yuju Ohno, Tomohiko Kamimura, Koji Nagafuji, Yasushi Takamatsu, Takanori Teshima, Hisashi Gondo, Shuichi Taniguchi, Koichi Akashi, Mine Harada

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We retrospectively analyzed the outcomes of 81 patients with non-M3 acute myelogenous leukemia (AML) in first complete remission (CR1) who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (Auto-PBSCT) by the Fukuoka Blood and Marrow Transplantation Group between 1989 and 2005. Cytogenetically, 16 patients were defined as good risk, 56 as intermediate risk, and nine as poor risk, following the Southwest Oncology Group criteria. The pre-transplant conditioning regimen consisted of high-dose busulfan, etoposide, and cytarabine (BEA regimen), combined with priming by granulocyte colony-stimulating factor (G-CSF). Disease-free survival (DFS) and overall survival at 5 years were 64.0 % (95 % CI 52.5-73.4) and 66.4 % (95 % CI 54.9-75.6) after Auto-PBSCT at a median follow-up time of 103 months (range 3-240 months), respectively. Two patients died of transplant-related pulmonary complications 6 months after Auto-PBSCT without relapse. The 5-year DFS rates of patients in the genetically good-, intermediate-, and poor-risk groups were 80.8, 64.3, and 33.3 %, respectively, but there was no significant difference statistically among the risk groups (log-rank p = 0.0579). These observations suggest that HDCT supported by Auto-PBSCT with the BEA regimen combined with G-CSF priming is a therapeutic option for postremission therapy of AML in CR1.

Original languageEnglish
Pages (from-to)186-196
Number of pages11
JournalInternational journal of hematology
Volume98
Issue number2
DOIs
Publication statusPublished - Aug 1 2013

Fingerprint

Peripheral Blood Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Acute Myeloid Leukemia
Disease-Free Survival
Transplants
Therapeutics
Drug Therapy
Busulfan
Cytarabine
Etoposide
Survival Rate
Transplantation
Bone Marrow
Recurrence
Lung
Survival

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. / Eto, Tetsuya; Takase, Ken; Miyamoto, Toshihiro; Ohno, Yuju; Kamimura, Tomohiko; Nagafuji, Koji; Takamatsu, Yasushi; Teshima, Takanori; Gondo, Hisashi; Taniguchi, Shuichi; Akashi, Koichi; Harada, Mine.

In: International journal of hematology, Vol. 98, No. 2, 01.08.2013, p. 186-196.

Research output: Contribution to journalArticle

Eto, Tetsuya ; Takase, Ken ; Miyamoto, Toshihiro ; Ohno, Yuju ; Kamimura, Tomohiko ; Nagafuji, Koji ; Takamatsu, Yasushi ; Teshima, Takanori ; Gondo, Hisashi ; Taniguchi, Shuichi ; Akashi, Koichi ; Harada, Mine. / Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. In: International journal of hematology. 2013 ; Vol. 98, No. 2. pp. 186-196.
@article{efb409a141bf4e428ce6f90eb7597180,
title = "Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission",
abstract = "We retrospectively analyzed the outcomes of 81 patients with non-M3 acute myelogenous leukemia (AML) in first complete remission (CR1) who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (Auto-PBSCT) by the Fukuoka Blood and Marrow Transplantation Group between 1989 and 2005. Cytogenetically, 16 patients were defined as good risk, 56 as intermediate risk, and nine as poor risk, following the Southwest Oncology Group criteria. The pre-transplant conditioning regimen consisted of high-dose busulfan, etoposide, and cytarabine (BEA regimen), combined with priming by granulocyte colony-stimulating factor (G-CSF). Disease-free survival (DFS) and overall survival at 5 years were 64.0 {\%} (95 {\%} CI 52.5-73.4) and 66.4 {\%} (95 {\%} CI 54.9-75.6) after Auto-PBSCT at a median follow-up time of 103 months (range 3-240 months), respectively. Two patients died of transplant-related pulmonary complications 6 months after Auto-PBSCT without relapse. The 5-year DFS rates of patients in the genetically good-, intermediate-, and poor-risk groups were 80.8, 64.3, and 33.3 {\%}, respectively, but there was no significant difference statistically among the risk groups (log-rank p = 0.0579). These observations suggest that HDCT supported by Auto-PBSCT with the BEA regimen combined with G-CSF priming is a therapeutic option for postremission therapy of AML in CR1.",
author = "Tetsuya Eto and Ken Takase and Toshihiro Miyamoto and Yuju Ohno and Tomohiko Kamimura and Koji Nagafuji and Yasushi Takamatsu and Takanori Teshima and Hisashi Gondo and Shuichi Taniguchi and Koichi Akashi and Mine Harada",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/s12185-013-1378-9",
language = "English",
volume = "98",
pages = "186--196",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission

AU - Eto, Tetsuya

AU - Takase, Ken

AU - Miyamoto, Toshihiro

AU - Ohno, Yuju

AU - Kamimura, Tomohiko

AU - Nagafuji, Koji

AU - Takamatsu, Yasushi

AU - Teshima, Takanori

AU - Gondo, Hisashi

AU - Taniguchi, Shuichi

AU - Akashi, Koichi

AU - Harada, Mine

PY - 2013/8/1

Y1 - 2013/8/1

N2 - We retrospectively analyzed the outcomes of 81 patients with non-M3 acute myelogenous leukemia (AML) in first complete remission (CR1) who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (Auto-PBSCT) by the Fukuoka Blood and Marrow Transplantation Group between 1989 and 2005. Cytogenetically, 16 patients were defined as good risk, 56 as intermediate risk, and nine as poor risk, following the Southwest Oncology Group criteria. The pre-transplant conditioning regimen consisted of high-dose busulfan, etoposide, and cytarabine (BEA regimen), combined with priming by granulocyte colony-stimulating factor (G-CSF). Disease-free survival (DFS) and overall survival at 5 years were 64.0 % (95 % CI 52.5-73.4) and 66.4 % (95 % CI 54.9-75.6) after Auto-PBSCT at a median follow-up time of 103 months (range 3-240 months), respectively. Two patients died of transplant-related pulmonary complications 6 months after Auto-PBSCT without relapse. The 5-year DFS rates of patients in the genetically good-, intermediate-, and poor-risk groups were 80.8, 64.3, and 33.3 %, respectively, but there was no significant difference statistically among the risk groups (log-rank p = 0.0579). These observations suggest that HDCT supported by Auto-PBSCT with the BEA regimen combined with G-CSF priming is a therapeutic option for postremission therapy of AML in CR1.

AB - We retrospectively analyzed the outcomes of 81 patients with non-M3 acute myelogenous leukemia (AML) in first complete remission (CR1) who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (Auto-PBSCT) by the Fukuoka Blood and Marrow Transplantation Group between 1989 and 2005. Cytogenetically, 16 patients were defined as good risk, 56 as intermediate risk, and nine as poor risk, following the Southwest Oncology Group criteria. The pre-transplant conditioning regimen consisted of high-dose busulfan, etoposide, and cytarabine (BEA regimen), combined with priming by granulocyte colony-stimulating factor (G-CSF). Disease-free survival (DFS) and overall survival at 5 years were 64.0 % (95 % CI 52.5-73.4) and 66.4 % (95 % CI 54.9-75.6) after Auto-PBSCT at a median follow-up time of 103 months (range 3-240 months), respectively. Two patients died of transplant-related pulmonary complications 6 months after Auto-PBSCT without relapse. The 5-year DFS rates of patients in the genetically good-, intermediate-, and poor-risk groups were 80.8, 64.3, and 33.3 %, respectively, but there was no significant difference statistically among the risk groups (log-rank p = 0.0579). These observations suggest that HDCT supported by Auto-PBSCT with the BEA regimen combined with G-CSF priming is a therapeutic option for postremission therapy of AML in CR1.

UR - http://www.scopus.com/inward/record.url?scp=84882287011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882287011&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1378-9

DO - 10.1007/s12185-013-1378-9

M3 - Article

C2 - 23754766

AN - SCOPUS:84882287011

VL - 98

SP - 186

EP - 196

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -